Alterity Therapeutics Limited, a biotechnology company listed on NASDAQ under the symbol 'ATHE', has announced a prospectus supplement for the offer and sale of ordinary shares represented by American Depositary Shares (ADSs), with an aggregate offering price of up to US$6,000,000. The ADSs are evidenced by American Depositary Receipts (ADRs). The company entered into a Sales Agreement with JonesTrading Institutional Services LLC on February 15, 2024, to act as the sales agent. The ADSs will be sold in 'at the market offerings' as defined under Rule 415 under the Securities Act of 1933. The closing price of an ADS on February 14, 2024, was US$1.98. The Agent will receive a commission of 3.0% of the gross sales price per share sold. Alterity Therapeutics has agreed to provide...Show More

Alterity Therapeutics Limited, a biotechnology company listed on NASDAQ under the symbol 'ATHE', has announced a prospectus supplement for the offer and sale of ordinary shares represented by American Depositary Shares (ADSs), with an aggregate offering price of up to US$6,000,000. The ADSs are evidenced by American Depositary Receipts (ADRs). The company entered into a Sales Agreement with JonesTrading Institutional Services LLC on February 15, 2024, to act as the sales agent. The ADSs will be sold in 'at the market offerings' as defined under Rule 415 under the Securities Act of 1933. The closing price of an ADS on February 14, 2024, was US$1.98. The Agent will receive a commission of 3.0% of the gross sales price per share sold. Alterity Therapeutics has agreed to provide indemnification and contribution to the Agent against certain liabilities. The company has previously sold US$118,061 of securities and will not exceed one-third of its public float in any 12-month period as long as the public float remains below US$75,000,000. Investing in the ADSs involves a high degree of risk, and potential investors are advised to read the 'Risk Factors' section beginning on page S-3 of the prospectus supplement.